Dries Dobbelaere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dries Dobbelaere has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Adrien Paquot
APTEEUS, Campus Inst Pasteur Lille,1 Rue Prof Calmette, F-59000 Lille, France
1 shared publication- Anita MacDonald
Dietetic Department, Birmingham Children’s Hospital, Birmingham, UK
1 shared publication Anne-Frédérique Dessein
Univ Lille, CHU Lille, Ctr Biol Pathol Genet, UF Metab Gen & Malad Rares, F-59000 Lille, France
1 shared publication- Anselma Riederer
Institute for Medical Information Processing, Biometry, and Epidemiology, Medical Faculty, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
1 shared publication Benoit Deprez
APTEEUS, Campus Inst Pasteur Lille,1 Rue Prof Calmette, F-59000 Lille, France
1 shared publicationCamille Moreau
APTEEUS, Campus Inst Pasteur Lille,1 Rue Prof Calmette, F-59000 Lille, France
1 shared publication
Latest Publications
- Open Access
- 10 October 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (4) , 92
Practical Considerations for the Diagnosis and Management of Isovaleryl-CoA-Dehydrogenase Deficiency (Isovaleric Acidemia): Systematic Search and Review and Expert Opinions
Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency of isovaleryl-CoA dehydrogenase (IVD), leading to an accumulation of isovaleric acid and its derivates 3-hydroxyisovaleric acid, isovaleryl (C5)-carnitine and isovalerylglycine in body fluids. The clinical presentation is highly variable, ranging from life-threatening metabolic crises with metabolic acidosis and hyperammonemia to a clinically asymptomatic only biochemical phenotype. Newborn screening for IVA has been established in many countries. Treatment consists of a protein-restricted diet combined with supplementation of carnitine and/or glycine and emergency treatment in catabolic episodes. Still, evidence-based recommendations for the diagnosis and management of IVA patients with various phenotypes are lacking. Therefore, a systematic search and review of the literature was conducted to make suggestions for the care of patients with IVA based on both the available scientific evidence and consensus-derived expert conclusions. Based on a comprehensive set of literature data published between 1966 and 2024, 15 statements were phrased on the presentation, diagnosis, management, and outcome of IVA involving clinical, biochemical, and nutrition expertise. These statements can serve as a basis for more standardized care for IVA.
- 10 October 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (4) , 92
Open AccessPractical Considerations for the Diagnosis and Management of Isovaleryl-CoA-Dehydrogenase Deficiency (Isovaleric Acidemia): Systematic Search and Review and Expert Opinions
Isovaleric acidemia (IVA, OMIM 243500) is an inherited disorder of leucine metabolism caused by a deficiency of isovaleryl-CoA dehydrogenase (IVD), leading to an accumulation of isovaleric acid and its derivates 3-hydroxyisovaleric acid, isovaleryl (C5)-carnitine and isovalerylglycine in body fluids. The clinical presentation is highly variable, ranging from life-threatening metabolic crises with metabolic acidosis and hyperammonemia to a clinically asymptomatic only biochemical phenotype. Newborn screening for IVA has been established in many countries. Treatment consists of a protein-restricted diet combined with supplementation of carnitine and/or glycine and emergency treatment in catabolic episodes. Still, evidence-based recommendations for the diagnosis and management of IVA patients with various phenotypes are lacking. Therefore, a systematic search and review of the literature was conducted to make suggestions for the care of patients with IVA based on both the available scientific evidence and consensus-derived expert conclusions. Based on a comprehensive set of literature data published between 1966 and 2024, 15 statements were phrased on the presentation, diagnosis, management, and outcome of IVA involving clinical, biochemical, and nutrition expertise. These statements can serve as a basis for more standardized care for IVA.
- 28 September 2024
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 143 (3) , 108581
Findings from the individualized management of a patient with Acyl-CoA Oxidase-1 (ACOX1) deficiency: A bedside-to-bench-to-bedside strategy
- 28 September 2024
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 143 (3) , 108581
Findings from the individualized management of a patient with Acyl-CoA Oxidase-1 (ACOX1) deficiency: A bedside-to-bench-to-bedside strategy